Picture Berlin Partner Life Sciences Report 2024-2025 650x100px

Product › Details

Erbitux®

	Next higher product group	cetuximab
	Status	2004-07-01 sales start
	Annual sales	USD 2,016,000,000 (sales (2013) 2013)
	Organisation	Merck KGaA
	Group	Merck (DE) (Group)
	Organisation 2	ImClone Systems Inc.
	Group	Eli Lilly (Group)
	Original research	Weizmann Institute of Science
	Source	Merck KGaA. (3/2/20). "Press Release: Erbitux Approved for First-Line Use in China in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) [Not intended for UK-based media]". Darmstadt.

Record changed: 2024-01-07

Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x200px

More documents for antibody cancer drug

[1] Daiichi Sankyo Co., Ltd.. (1/13/25). "Press Release: Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH". Tokyo & Basking Ridge, NJ....
[2] Ottimo Pharma Ltd.. (12/19/24). "Press Release: Ottimo Pharma Raises over $140 Million in Series A Financing". London & Boston, MA....
[3] Agilent Technologies Inc.. (12/10/24). "Press Release: Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification". Santa Clara, CA....
[4] Ipsen S.A.. (12/3/24). "Press Release: Ipsen and Biomunex Announce Exclusive Global Licensing Agreement for First-in-Class MAIT Cell Engager in Immuno-oncology". Paris....
[5] BioNTech SE. (11/13/24). "Press Release: BioNTech to Acquire Biotheus to Boost Oncology Strategy". Mainz....
[6] Ottimo Pharma Ltd.. (10/28/24). "Press Release: Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 20...
[7] Dren Bio, Inc.. (7/24/24). "Press Release: Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer". Foster City, CA....
[8] Catalym GmbH. (7/16/24). "Press Release: Catalym Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab". Munich....
[9] Apeiron Biologics AG. (7/8/24). "Press Release: Apeiron Biologics to Be Acquired by Ligand Pharmaceuticals for USD 100 Million". Vienna....
[10] Tacalyx GmbH. (6/11/24). "Press Release: Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]